Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore Device for the Relief of EIB
NCT ID: NCT01923272
Last Updated: 2013-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2012-10-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objectives of this study are (1) to gather preliminary safety and efficacy data of the AlphaCore device for the treatment of EIB (Treatment Visit 1) and prevention of EIB (Treatment Visit 2), (2) to validate the sham device (blinding effects, placebo effect) as an effective control for use in future clinical studies, and (3) to support the development and approval of a pivotal study, confirm data collection methods and endpoint definitions, and confirm appropriateness of the subject follow up plan.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Number of Study Visits: Three:
1. Screening Visit
2. Treatment Visit 1 - treatment with AlphaCore (active or sham) after exercise challenge
3. Treatment Visit 2 - Prophylactic treatment with AlphaCore (active or sham) prior to exercise challenge
There will be a telephone follow-up call within 12-24 hours after the treatment visits occur as well as a 7-day (+/- 3 days) final phone call after Treatment Visit 2.
\# of Study Arm(s): Two Arms
1. Active Treatment with the AlphaCore Device
2. Sham Treatment with an inactive sham device Blinding Double blind. The subject will be blinded to treatment assignment. Due to the treating Investigator's or designee designee's ability to detect differences in muscle effects between the active and sham device, the treating Investigator or designee cannot be blinded. Data assessors will be blinded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sham Device
inactive AlphaCore device
AlphaCore Device
Active stimulation to the vagal nerve
AlphaCore
Active AlphaCore treatment
AlphaCore
Active AlphaCore device
AlphaCore Device
Active stimulation to the vagal nerve
AlphaCore
Active AlphaCore treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AlphaCore Device
Active stimulation to the vagal nerve
AlphaCore
Active AlphaCore treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Is between the ages of 18 and 60 years, male or female.
3. Has a history of breathlessness during and after exertion.
4. Normally controls or prevents EIB using a short acting beta-agonist (SABA).
5. Is willing to take a urine pregnancy test if female of childbearing potential and agrees not to become pregnant for the duration of the study.
Exclusion Criteria
2. Is unable to perform acceptable-quality spirometry (FEV1 \< 75% predicted).
3. Is currently using Beta2-adrenergic blockers (i.e. propranolol).
4. Has smoked within the past year, and/or more than 10 pack year history.
5. Has a history of lung cancer, chronic obstructive pulmonary disease (COPD), or other co-morbidity associated with irreversible narrowing of the airways.
6. Has an abscess or other infection or lesion (including lymphadenopathy) at the AlphaCore treatment site.
7. Has known or suspected moderate to severe atherosclerotic cardiovascular disease, carotid artery disease (e.g. bruits or history of TIA or CVA).
8. Has a clinically significant irregular heart rate or rhythm.
9. Has uncontrolled hypertension (systolic bp \> 200 or diastolic bp \>100), recent (within the last 3 months) heart attack, recent (within the last 3 months) stroke, known aortic aneurysm, or congestive heart failure (CHF).
10. Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
11. Has a history of carotid endarterectomy, vagotomy (right or bilateral), dysaesthesia or vascular neck surgery on the right side.
12. Has been implanted with metal cervical spine hardware.
13. Has a recent or repeated history of syncope.
14. Has a recent or repeated history of seizures.
15. Has a condition that would interfere with VAS Dyspnea self-assessment.
16. Is pregnant or nursing, or of childbearing potential and is unwilling to use an accepted form of birth control.
17. Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.
18. Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g., homeless, developmentally disabled, prisoner).
19. Is an employee or relative of the Investigator or the clinical study site.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ElectroCore INC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Weiman
Role: STUDY_DIRECTOR
ElectroCore INC
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BC-US-07
Identifier Type: -
Identifier Source: org_study_id